Dropout Risk and Effectiveness of Retention Strategies in the Memory Advancement by Intranasal Insulin in Type 2 Diabetes (MemAID) Clinical Trial

Overview

Journal Contemp Clin Trials

Publisher Elsevier

Date 2022 Dec 20

PMID 36539060

Authors

Daniel F Isaza-Pierrotti

Faizan Khan

Peter Novak

Vasileios Lioutas

C S Mantzoros

Long H Ngo

Vera Novak

Affiliations

Soon will be listed here.

Abstract

Background: Effective recruitment and retention strategies are essential in clinical trials.

Methods: The MemAID trial consisted of 12 visits during 24 weeks of intranasal insulin or placebo treatment and 24 weeks of post-treatment follow-up in older people with and without diabetes. Enhanced retention strategies were implemented mid study to address high drop-out rate. Baseline variables used in Cox regression models to identify dropout risk factors were: demographics and social characteristics, functional measures, metabolic and cardiovascular parameters, and medications.

Results: 244 participants were randomized; 13 (5.3%) were discontinued due to adverse events. From the remaining 231 randomized participants, 65 (28.1%) dropped out, and 166 (71.9%) did not. The Non-retention group included 95 participants not exposed to retention strategies, of which 43 (45.2%) dropped out. The Retention group included 136 participants exposed to enhanced retention strategies, of which 22 (16.2%) dropped out. Dropout risk factors included being unmarried, a longer diabetes duration, using oral antidiabetics as compared to not using, worse executive function and chronic pain. After adjusting for exposure to retention strategies, worse baseline executive function composite score (p = 0.001) and chronic pain diagnosis (p = 0.032) were independently associated with a greater risk of dropping out. The probability of dropping out decreased with longer exposure to retention strategies and the dropout rate per month decreased from 4.1% to 1.8% (p = 0.04) on retention strategies.

Conclusions: Baseline characteristics allow prediction of dropping out from a clinical trial in older participants. Retention strategies has been effective at minimizing the impact of dropout-related risk factors.

Trial Registration: Clinical trials.gov NCT2415556 3/23/2015 (www.

Clinicaltrials: gov).

References

Wooten T, Sullivan D, Logue M, Fonda J, Fortier C, DeGutis J . Apolipoprotein E () ε4 Status Moderates the Relationship Between Close-Range Blast Exposure and Cognitive Functioning. J Int Neuropsychol Soc. 2020; 27(4):315-328. DOI: 10.1017/S1355617720001034. View

Novak V, Mantzoros C, Novak P, McGlinchey R, Dai W, Lioutas V . MemAID: Memory advancement with intranasal insulin vs. placebo in type 2 diabetes and control participants: a randomized clinical trial. J Neurol. 2022; 269(9):4817-4835. PMC: 9046533. DOI: 10.1007/s00415-022-11119-6. View

Caballero J, Ownby R, Jacobs R, Pandya N, Hardigan P, Ricabal L . Predicting medication adherence in older Hispanic patients with type 2 diabetes. Am J Health Syst Pharm. 2018; 75(9):e194-e201. DOI: 10.2146/ajhp170067. View

Robinson K, Dinglas V, Sukrithan V, Yalamanchilli R, Mendez-Tellez P, Dennison-Himmelfarb C . Updated systematic review identifies substantial number of retention strategies: using more strategies retains more study participants. J Clin Epidemiol. 2015; 68(12):1481-7. PMC: 4658250. DOI: 10.1016/j.jclinepi.2015.04.013. View

Stubbs B, Schofield P, Patchay S . Mobility Limitations and Fall-Related Factors Contribute to the Reduced Health-Related Quality of Life in Older Adults With Chronic Musculoskeletal Pain. Pain Pract. 2014; 16(1):80-9. DOI: 10.1111/papr.12264. View

Galindo-Mendez B, Trevino J, McGlinchey R, Fortier C, Lioutas V, Novak P . Memory advancement by intranasal insulin in type 2 diabetes (MemAID) randomized controlled clinical trial: Design, methods and rationale. Contemp Clin Trials. 2020; 89:105934. PMC: 7242142. DOI: 10.1016/j.cct.2020.105934. View

Clark M, Niaura R, King T, Pera V . Depression, smoking, activity level, and health status: pretreatment predictors of attrition in obesity treatment. Addict Behav. 1996; 21(4):509-13. DOI: 10.1016/0306-4603(95)00081-x. View

Sood A, Prasad K, Chhatwani L, Shinozaki E, Cha S, Loehrer L . Patients' attitudes and preferences about participation and recruitment strategies in clinical trials. Mayo Clin Proc. 2009; 84(3):243-7. PMC: 2664601. DOI: 10.4065/84.3.243. View

Bower P, Brueton V, Gamble C, Treweek S, Tudur Smith C, Young B . Interventions to improve recruitment and retention in clinical trials: a survey and workshop to assess current practice and future priorities. Trials. 2014; 15:399. PMC: 4210542. DOI: 10.1186/1745-6215-15-399. View

10.

Brueton V, Tierney J, Stenning S, Harding S, Meredith S, Nazareth I . Strategies to improve retention in randomised trials. Cochrane Database Syst Rev. 2013; (12):MR000032. PMC: 4470347. DOI: 10.1002/14651858.MR000032.pub2. View

11.

Honas J, Early J, Frederickson D, OBrien M . Predictors of attrition in a large clinic-based weight-loss program. Obes Res. 2003; 11(7):888-94. DOI: 10.1038/oby.2003.122. View

12.

Forsat N, Palmowski A, Palmowski Y, Boers M, Buttgereit F . Recruitment and Retention of Older People in Clinical Research: A Systematic Literature Review. J Am Geriatr Soc. 2020; 68(12):2955-2963. DOI: 10.1111/jgs.16875. View

13.

Aponte Becerra L, Galindo Mendez B, Khan F, Lioutas V, Novak P, Mantzoros C . Safety of Intranasal Insulin in Type 2 Diabetes on Systemic Insulin: A Double-Blinded Placebo-Controlled Sub-Study of Memaid Trial. Arch Diabetes Obes. 2022; 4(2):403-415. PMC: 9328174. View

14.

Mohseni S, Tabatabaei-Malazy O, Peimani M, Ejtahed H, Khodaeian M, Nazeri E . Withdrawal reasons of randomized controlled trials on type 2 diabetes: a systematic review. Daru. 2021; 29(1):39-50. PMC: 8149490. DOI: 10.1007/s40199-020-00380-7. View

15.

Ross S, Grant A, Counsell C, Gillespie W, Russell I, Prescott R . Barriers to participation in randomised controlled trials: a systematic review. J Clin Epidemiol. 1999; 52(12):1143-56. DOI: 10.1016/s0895-4356(99)00141-9. View

16.

Walters S, Dos Anjos Henriques-Cadby I, Bortolami O, Flight L, Hind D, Jacques R . Recruitment and retention of participants in randomised controlled trials: a review of trials funded and published by the United Kingdom Health Technology Assessment Programme. BMJ Open. 2017; 7(3):e015276. PMC: 5372123. DOI: 10.1136/bmjopen-2016-015276. View

17.

Sawamoto R, Nozaki T, Furukawa T, Tanahashi T, Morita C, Hata T . Predictors of Dropout by Female Obese Patients Treated with a Group Cognitive Behavioral Therapy to Promote Weight Loss. Obes Facts. 2016; 9(1):29-38. PMC: 5644900. DOI: 10.1159/000442761. View

18.

Chaudhari N, Ravi R, Gogtay N, Thatte U . Recruitment and retention of the participants in clinical trials: Challenges and solutions. Perspect Clin Res. 2020; 11(2):64-69. PMC: 7342338. DOI: 10.4103/picr.PICR_206_19. View

19.

Abshire M, Dinglas V, Cajita M, Eakin M, Needham D, Himmelfarb C . Participant retention practices in longitudinal clinical research studies with high retention rates. BMC Med Res Methodol. 2017; 17(1):30. PMC: 5319074. DOI: 10.1186/s12874-017-0310-z. View